Dow Transform to Outperform Costs Create Q2 SGA Distortion; Deleveraging in Focus

Dow Transform to Outperform: Are SG&A (the “535”) normal, and how to think about dilution vs. using cash

1) Is the “535 number” (reported) a normal run-rate or abnormal?

From the excerpted earnings discussion, we don’t get the exact identity of the “535 number” (i.e., whether it’s SG&A of $535 million, or a specific “SAR”/other cost line, or something else). What we can support directly is the management explanation for why certain transformation-related cost lines looked worse in Q2 and how they expect those numbers to improve in later quarters.

What management said about “abnormal” Q2 costs related to Transform to Outperform

Management attributed Q2 strength in SAR being temporarily overshadowed by two “sizable items” that were specific to the quarter:

• Onetime significant items associated with costs related to Transform to Outperform that “you will see reflect in SAR area.” ¹
• Increased performance-based compensation tied to results. ¹

They also said their SAR otherwise remains top quartile and close to 6% (best-in-class), but those quarter-specific items overshadow the continued improvement they were seeing from “self-help actions.” ¹

What they expect going forward

They explicitly guided that as they ramp self-help actions into the second half, SAR numbers should come down from what was seen in Q2. ¹ That is management’s own framing of temporary Q2 distortion rather than a new permanent run-rate.

Reconciling this with the SG&A question you asked

Your premise is that SG&A increased ~$200 million YoY and ~$100 million sequentially, and rose ~1 percentage point of sales. Those exact SG&A figures are not stated in the provided excerpts, so they can’t be confirmed from the filings you supplied. However, the excerpt does establish a plausible mechanism for why corporate overhead / SAR-like cost metrics could spike in Q2 during a transformation program:

• Quarter-specific onetime Transform-related costs and performance comp inflated the relevant cost lines in that quarter. ¹
• Management expects those distortionary drivers to abate as the program actions ramp into the second half. ¹

Bottom line on “535 number”

Given management’s explicit characterization of Q2 cost-line pressure as driven by (1) one-time Transform costs and (2) performance-based compensation, the most supported answer is: the reported “535” is more consistent with an abnormal/temporary Q2 spike than a normal run-rate, to the extent the “535” corresponds to the SAR/cost line management was discussing in that exchange. ¹
If the “535 number” you’re referring to is a different line item than SAR/cost of transformation, the excerpt doesn’t provide enough detail to determine whether it is normal versus abnormal.

2) Should Dow use cash flow to offset dilution from share issuance, given a “high cost of equity” narrative and a low share price?

The excerpt provides guidance on capital allocation priorities, but it does not explicitly address the specific “use cash to offset dilution from share issuance” strategy (e.g., buyback timing relative to issuance). So the analysis must remain within what management said.

What management prioritized for excess cash

Management’s capital allocation framework emphasized:

• Investment-grade credit profile and pay down debt as the first priority, including ~$1 billion of debt accumulated over the prior 12 months. ¹
• They also said they paid off ~ $80 million of debt in Q2. ¹
• Regarding excess cash, they said that with improved earnings and cash conversion, they will prioritize excess cash toward deleveraging. ²
• They also stated expectation of no substantive share buybacks during 2026 (“the expectation is that we would not have those during the course of 2026”). ³

Implication for the “offset dilution with buybacks” idea

Given the explicit statement that they expect no substantive buybacks during 2026 and that excess cash is prioritized for deleveraging, management’s disclosed approach is essentially the opposite of “use cash flow to offset dilution via buybacks (because the share price is low and equity is expensive).” ³
In other words, even if a shareholder could argue that repurchasing shares at a low price could be economically attractive, the company’s stated plan (at least over 2026) is to direct cash to debt reduction and balance sheet flexibility rather than share repurchases. ³¹²

Does the “high cost of equity / low share price” rationale appear in management’s remarks?

The excerpts do not quantify a “cost of equity” or mention share-price relative-history as a decision input. Instead, management anchored the rationale around:

• Credit profile and leverage/liability management, and
• Liquidity and financial flexibility (e.g., ~$14 billion total available liquidity is cited). ²
• A minimum release of >$500 million from working capital efforts in H2 is also cited as a cash source. ²

So, with the evidence provided, you can’t conclude that management is willing to accept dilution “because the share price is low” or reject it because “equity is expensive.” The only directly supported conclusion is: their disclosed hierarchy is debt paydown and balance-sheet strengthening first, and they do not expect substantive buybacks in 2026. ³¹²

What about the transformation program’s own cash economics?

The excerpted Transform to Outperform discussion emphasizes EBITDA uplift and ramp, not share count/capital structure mechanics:

• ~55% of planned Dow role reductions implemented, expected to contribute >$200 million EBITDA uplift in the second half. ⁴
• Site transformation playbook completed at 6 of largest sites, expected about $50 million in EBITDA uplift in the second half. ⁴
• They also talk about an expectation of ~$700 million benefit from Transform to Outperform in 2026 and improving through the year. ⁵

That supports the idea that they want transformation to improve cash/earnings capacity, which then supports their deleveraging priority—consistent with their stated capital allocation plan (deleveraging first). ¹²

Final answers (directly to your two questions)

1. Normal or abnormal “535 number”?
   Based on management’s explanation for Q2 transformation-related cost pressure—specifically onetime Transform costs reflected in SAR and increased performance-based compensation—and their guidance that SAR cost lines should come down as self-help ramps, the “535” (if it maps to the SAR/cost-line management discussed) appears abnormal/temporary for Q2 rather than a steady normal run-rate. ¹

2. Should cash flow be used to offset dilution from share issuance due to high equity cost/low share price?
   The excerpts show management’s capital allocation priorities as deleveraging and maintaining investment-grade profile, including ~$80 million debt paid in Q2, and they explicitly state an expectation of no substantive share buybacks during 2026. ¹³ Therefore, within what’s disclosed here, the company is not signaling a strategy of using cash to offset dilution via buybacks; instead, it’s prioritizing debt reduction and balance sheet flexibility. ³¹²

If you clarify exactly what the “535 number” refers to (which line item and whether it’s SAR/SG&A/another metric), I can tie it even more precisely to the specific drivers management listed in the excerpt.